NEW YORK, April 20 / PRNewswire / - Keryx Biopharmaceuticals, Inc. ( Nasdaq Nasdaq : KERX - News ) gab heute bekannt, dass vorklinische Daten in Neuroblastom für KRX-0401 (Perifosin), der Firma Roman, potenziell first-in-class, orale Krebsmedikament, dass die Aktivierung hemmt Akt in der Phosphoinositid 3-kinase (PI3K)-Weg , DC, vorgestellt werden auf der 101. Jahrestagung der American Association for Cancer Research (AACR), hielt die derzeit in Washington.
Das folgende Plakat wird in Exhibit Hall präsentiert werden AC am MITTWOCH, 21 April, 2010, von 8:00 Uhr-11: 00am:
KERYX BIOPHARMACEUTICALS, INC. 750 Lexington Avenue New York, New York 10022
You are cordially invited to our 2010 Annual Meeting of Stockholders, to be held at 10:00 a.m. local time, on Tuesday, June 15, 2010, at the offices of our legal counsel, Alston & Bird LLP, located at 90 Park Avenue, New York, New York 10016. At the meeting, the stockholders will be asked to (i) elect five directors for a term of one year and (ii) ratify the appointment of UHY LLP as our independent registered public accounting firm for the year ending December 31, 2010. You will also have the opportunity to ask questions and make comments at the meeting.
In accordance with the rules and regulations of the Securities and Exchange Commission, we are furnishing our proxy statement and annual report to stockholders for the year ended December 31, 2009 on the Internet. You may have already received our ?Important Notice Regarding the Availability of Proxy Materials,? which was mailed on or about April 30, 2010. That notice describes how you can obtain our proxy statement and annual report. You can also receive paper copies of our proxy statement and annual report upon request.
It is important that your stock be represented at the meeting regardless of the number of shares you hold. You are encouraged to specify your voting preferences by marking our proxy card and returning it as directed. If you do attend the meeting and wish to vote in person, you may revoke your proxy at the meeting.
If you have any questions about the proxy statement or the accompanying 2009 annual report, please contact James F. Oliviero, our Chief Financial Officer, Treasurer and Corporate Secretary at (212) 531-5965.
We look forward to seeing you at the 2010 Annual Meeting.
§ Sincerely, /s/ Ron Bentsur Ron Bentsur Chief Executive Officer